 BILLERICA, Mass.--BUSINESS WIRE--Quanterix Corporation NASDAQ:QTRX, a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration FDA has issued an Emergency Use Authorization EUA for its Simoa SARS-CoV-2 N Protein Antigen Test that can be run on the Simoa HD-X Analyzer, a fully automated high-throughput immunoassay instrument. The Simoa SARS-CoV-2 N Protein Antigen Test detects the presence of the SARS-CoV-2 